Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

SOUTH SAN FRANCISCO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today provided a clinical update on voreloxin, its novel investigational drug candidate currently being developed in Phase 2 trials for acute myeloid leukemia (AML) and ovarian cancer. The clinical update coincides with the company's attendance at the 27th Annual JP Morgan Healthcare Conference in San Francisco.

"2008 was an important year for Sunesis, as we have continued to advance the development of voreloxin in both AML and ovarian cancer. We believe voreloxin has the potential to be a first-in-class anti-cancer agent for treating these diseases and potentially other hematologic and solid tumors," said Daniel Swisher, Chief Executive Officer and President of Sunesis. "We completed enrollment of our Phase 2 platinum-resistant ovarian cancer study and both of our ongoing AML studies are enrolling well, with 45 AML patients enrolled in the fourth quarter of 2008 alone. In the first half of 2009, we anticipate reporting additional data from all three of our ongoing voreloxin studies. We remain on track to initiate a pivotal voreloxin study in AML by the end of this year."

Sunesis is providing an update on the progress of its voreloxin clinical trials as follows:

Phase 2 and 1b/2 Studies of Voreloxin in AML

Sunesis is evaluating single agent voreloxin in an ongoing Phase 2 trial, known as REVEAL-1, in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy. Interim results recently presented at the 50th Annual Meeting of the American Society of Hematology (ASH) show that voreloxin induces complete remissions in these poor risk patients. At ASH, outcome for the 29 patients enrolled and treated with Schedule A, 72 mg/m2 of vo
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... of the interesting and challenging endeavors as the ... highly impervious properties to the foreign substances. Ocular ... possibility of self medication and minimal use of ... molecular weight drugs and provides specific targeting within ...
(Date:8/22/2014)... Nerium International, the go-to, buzzworthy skincare ... again. Nerium will showcase its signature NeriumAD® Age-Defying ... Cream to Hollywood’s elite at the official Giving ... Primetime Emmy® Awards. , Developed from cutting-edge research ... show that NeriumAD night cream dramatically reduces the ...
(Date:8/21/2014)... the Institute for Molecular Medicine Finland (FIMM), University ... a novel "man and machine" decision support system ... was described in PLOS One scientific ... on computer vision algorithms similar to those used ... only the diagnostically most relevant areas. Tablet computers ...
(Date:8/21/2014)... SPRING, N.Y. , Aug. 21, 2014 /PRNewswire/ ... the launch of their Nutraceutical "TELO-20 for Dogs" ... and only Telomere-lengthening supplement in the world for ... ends of every chromosome in the body. A ... world,s leading experts in Telomere Science and Aging, ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3
... NEW YORK, Dec. 20 MacAndrews & Forbes ... Executive Vice President for Life,Sciences, who also serves ... been named to the National Biodefense Science Board ... to HHS Secretary Mike Leavitt,on scientific, technical and ...
... to ... Stockholders, SOUTH ... (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ), Dear Stockholder:, As you are ... respective Boards of Directors had unanimously,approved the merger of the two ...
... Member Brings Life Sciences Tools Experience to the Leader in ... Cellular ... Bioscience, the,leading provider of tools for real-time measurement of cellular,bioenergetics ... has been appointed to the company,s Board of,Directors. In this ...
Cached Biology Technology:Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board 2VaxGen Addresses MPM Claims in Letter to Stockholders 2VaxGen Addresses MPM Claims in Letter to Stockholders 3VaxGen Addresses MPM Claims in Letter to Stockholders 4VaxGen Addresses MPM Claims in Letter to Stockholders 5VaxGen Addresses MPM Claims in Letter to Stockholders 6VaxGen Addresses MPM Claims in Letter to Stockholders 7VaxGen Addresses MPM Claims in Letter to Stockholders 8VaxGen Addresses MPM Claims in Letter to Stockholders 9Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors 2
(Date:8/22/2014)... French . NAIROBI ... African soils looming as a major threat to food security ... over the last five years, 1.7 million African farmers in ... million hectares and helped them double or even triple crop ... Revolution in Africa (AGRA) focuses on intensive efforts initiated five ...
(Date:8/22/2014)... This news release is available in German . ... certain helper substances, in PCFs proteins are fixated in ... highly stable crystals. Next, the HZB and Fudan University ... be used as functional materials. Their findings are being ... (DOI: 10.1038/ncomms5634). , Proteins are sensitive molecules. Everyone ...
(Date:8/22/2014)... and the bees. But that old expression leaves ... fertilization process for flowering plants is particularly complex ... female reproductive cells. New research from an international ... including Carnegie,s Wolf Frommer, David Ehrhardt, and Guido ... that guides flowering plant fertilization. It is published ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4Proteins: New class of materials discovered 2Calcium and reproduction go together 2
... from Rice University's Center for Biological and Environmental ... are the most effective catalysts yet identified for ... and troublesome groundwater pollutants, trichloroethene or TCE. , ... the Georgia Institute of Technology, will appear next ...
... according to research published this week (24 Feb) in the ... British Antarctic Survey (BAS). , A study of George VI ... show that this currently 'healthy' ice shelf experienced an extensive ... recent years. The retreat coincided with a shift in ocean ...
... at Children's Hospital Boston and Harvard Medical School have ... virus (HIV) changes shape, triggering other changes that allow ... findings, published in the Feb. 24 issue of the ... and treatment approaches. , Researchers led by Howard Hughes ...
Cached Biology News:Tiny particles could solve billion-dollar problem 2Tiny particles could solve billion-dollar problem 3Antarctic ice shelf retreats happened before 2Elusive HIV shape change revealed; Key clue to how virus infects cells 2
... The QPatch sports 16-independent channels for ... is used for screening against voltage-gated ion ... such as GABA channels. The four ... faster throughput for ion channel drug discovery. ...
... systems need to be able to handle larger ... ports, as well as interface with telemetry systems. ... more, particularly with dogs, pigs, and primates. ... starting time, and the computer can be located ...
... Plate is a 96-well ELISA-compatible plate ... antibody (mouse IgG 1 ) is ... glutathione-S-transferase (GST), and binds with high ... protein in which the tag is ...
... projects are focused on sequencing, analysis of ... other areas of genomics and proteomics, EvoQuest ... meet your research and manufacturing challenges. Invitrogen ... your project from beginning to end in ...
Biology Products: